At Bottneuro AG, we are a team of dedicated individuals who are passionate about improving the diagnosis and treatment of neurological diseases.
Our team consists of biologists, materials scientists, engineers, data scientists, physicists and psychologists, and is backed up by highly experienced advisors and entrepreneurs, who bring a wealth of knowledge and experience to our mission.
Founded in 2021, Bottneuro AG is a cutting-edge medtech startup focused on improving the diagnosis and treatment of neurological diseases.
As a spin-off from the University of Basel, the company has quantitatively validated the positive effects of alternating microcurrents on glial cells, with financial support from the Gebert Rüf Stiftung. In its first year, Bottneuro successfully won all three stages of the Venture Kick Program and was recognized by Forbes Magazine as a spin-off to watch in the DACH region, solidifying its position as a leader in non-invasive treatment for Alzheimer's disease.
Inspiration comes of working every day - but only with a positive mindset. I want to ensure that technology simplifies the everyday life of all those who are particularly challenged by health issues.
I am convinced that by expanding our knowledge about neurodegenerative diseases we are able to limit and counteract harmful disease progression.
At Bottneuro, I have taken on the challenge of digital therapy for neurodegenerative diseases, helping to expand the technology and push it towards personalised treatment.
I am fascinated about psychology and neuroscience to better understand human behavior.
I studied business and economics at University in Basel before turning to medical informatics at FHNW in Muttenz/Olten.
I'm inspired to help treat neurodegenerative diseases at Bottneuro.